Trial Profile
Phase II Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Squamous Carcinoma After Failure of Conventional Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2023
Price :
$35
*
At a glance
- Drugs Icotinib (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 14 Feb 2023 Status changed from recruiting to completed.
- 31 Jan 2018 Planned end date changed from 1 Dec 2017 to 1 Dec 2018.
- 31 Jan 2018 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.